Importer of Controlled Substances; Notice of Registration, 2618-2619 [E9-731]
Download as PDF
<![CDATA[
2618
Federal Register / Vol. 74, No. 10 / Thursday, January 15, 2009 / Notices
—Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of this information
collection:
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Certification of Secure Gun Storage or
Safety Devices.
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Form Number: ATF F
5300.42. Bureau of Alcohol, Tobacco,
Firearms and Explosives.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Business or other forprofit. Other: None. The requested
information will be used to ensure that
applicants for a federal firearms license
are in compliance with the requirements
pertaining to the availability of secure
gun storage or safety devices.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 61,641
respondents will complete a 1 minute
form.
(6) An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 1,233
annual total burden hours associated
with this collection.
If additional information is required
contact: Lynn Bryant, Department
Clearance Officer, Policy and Planning
Staff, Justice Management Division,
Department of Justice, Patrick Henry
Building, Suite 1600, 601 D Street NW.,
Washington, DC 20530.
Dated: January 9, 2009.
Lynn Bryant,
Department Clearance Officer, PRA, United
States Department of Justice.
[FR Doc. E9–737 Filed 1–14–09; 8:45 am]
BILLING CODE 4410–FY–P
DEPARTMENT OF JUSTICE
jlentini on PROD1PC65 with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 9, 2008, and
published in the Federal Register on
October 17, 2008 (73 FR 61908),
Noramco Inc., 500 Swedes Landing
VerDate Nov<24>2008
18:58 Jan 14, 2009
Jkt 217001
Road, Wilmington, Delaware 19801–
4417, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Opium, Raw (9600) and Concentrate of
Poppy Straw (9670), basic classes of
controlled substances listed in schedule
II.
The company plans to import the
listed controlled substances to
manufacture other controlled
substances.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a)
and determined that the registration of
Noramco, Inc., to import the basic class
of controlled substance is consistent
with the public interest, and with
United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Noramco, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–773 Filed 1–14–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 9, 2008, and
published in the Federal Register on
October 17, 2008, (73 FR 61909),
Formulation Technologies LLC., 11400
Burnet Road, Suite 4010, Austin, Texas
78758, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Fentanyl (9801), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for analytical
characterization, secondary packaging,
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
and/or for distribution to clinical trial
sites.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Formulation Technologies LLC. to
import the basic class of controlled
substance is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Formulation Technologies
LLC. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–720 Filed 1–14–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 9, 2008, and
published in the Federal Register on
October 17, 2008, (73 FR 61908), Fisher
Clinical Services, Inc., 7554 Schantz
Road, Allentown, Pennsylvania 18106,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for analytical
research and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Fisher Clinical Services, Inc. to import
the basic class of controlled substance is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Fisher
E:\FR\FM\15JAN1.SGM
15JAN1
Federal Register / Vol. 74, No. 10 / Thursday, January 15, 2009 / Notices
Clinical Services, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR § 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–731 Filed 1–14–09; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
jlentini on PROD1PC65 with NOTICES
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 6, 2008, and
published in the Federal Register on
October 14, 2008, (73 FR 60719),
Hospira Inc., 1776 North Centennial
Drive, McPherson, Kansas 67460–1247,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Hospira, Inc. to import the basic class of
controlled substance is consistent with
the public interest, and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Hospira, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
VerDate Nov<24>2008
18:58 Jan 14, 2009
Jkt 217001
the basic class of controlled substance
listed.
DEPARTMENT OF JUSTICE
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–732 Filed 1–14–09; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
BILLING CODE 4410–09–P
2619
By Notice dated October 2, 2008, and
published in the Federal Register on
October 8, 2008, (73 FR 58979), Clinical
Supplies Management, Inc., 342 42nd.
Street, South Fargo, North Dakota
58103, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for clinical
trials, research, and analytical purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Supplies Management, Inc. to
import the basic class of controlled
substance is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Clinical Supplies
Management, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–733 Filed 1–14–09; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 2, 2008 and
published in the Federal Register on
October 8, 2008, (73 FR 58979), National
Center for Natural Products Research—
NIDA MProject, University of
Mississippi, 135 Coy Waller Complex,
University, Mississippi 38677, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) ......
Frm 00112
Fmt 4703
Sfmt 4703
I
I
The company plans to cultivate
marihuana for the National Institute on
Drug Abuse for research approved by
the Department of Health and Human
Services.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
National Center for Natural Products
Research—NIDA MProject to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated National Center for Natural
Products Research—NIDA MProject to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–719 Filed 1–14–09; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
PO 00000
Schedule
E:\FR\FM\15JAN1.SGM
15JAN1
]]>Agencies
[Federal Register Volume 74, Number 10 (Thursday, January 15, 2009)]
[Notices]
[Pages 2618-2619]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-731]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated October 9, 2008, and published in the Federal
Register on October 17, 2008, (73 FR 61908), Fisher Clinical Services,
Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as an importer of Noroxymorphone (9668), a basic class of
controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
analytical research and clinical trials.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the
registration of Fisher Clinical Services, Inc. to import the basic
class of controlled substance is consistent with the public interest,
and with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971, at this time. DEA
has investigated Fisher
[[Page 2619]]
Clinical Services, Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR Sec.
1301.34, the above named company is granted registration as an importer
of the basic class of controlled substance listed.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-731 Filed 1-14-09; 8:45 am]
BILLING CODE 4410-09-P
